Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Inventory (2020 - 2026)

Maxcyte has reported Inventory over the past 6 years, most recently at $7.5 million for Q4 2025.

  • Quarterly Inventory fell 15.34% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, down 15.34% year-over-year, with the annual reading at $7.5 million for FY2025, 15.34% down from the prior year.
  • Inventory was $7.5 million for Q4 2025 at Maxcyte, down from $7.6 million in the prior quarter.
  • Over five years, Inventory peaked at $12.5 million in Q3 2023 and troughed at $4.1 million in Q3 2021.
  • The 5-year median for Inventory is $8.3 million (2025), against an average of $8.6 million.
  • Year-over-year, Inventory surged 90.71% in 2022 and then plummeted 30.82% in 2025.
  • A 5-year view of Inventory shows it stood at $5.2 million in 2021, then soared by 64.87% to $8.6 million in 2022, then skyrocketed by 42.51% to $12.2 million in 2023, then fell by 27.11% to $8.9 million in 2024, then decreased by 15.34% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Inventory are $7.5 million (Q4 2025), $7.6 million (Q3 2025), and $7.9 million (Q2 2025).